| Literature DB >> 29706086 |
Shamsudini Hashi1, Courtney Rory Goodwin2, Ali Karim Ahmed1, Daniel M Sciubba1.
Abstract
Extranodal lymphoma of the spine is often a late manifestation of systemic disease, and may result in symptoms of pain, neurologic compromise or spinal instability. Symptomatic relief is generally achieved by radiotherapy alone, but is not sufficient in addressing spinal instability. The indications for surgery remain controversial, but may be required for spinal stabilization, or refractory disease. Currently, there is a lack of studies that compare the indications and clinical outcomes of patients receiving surgical and nonsurgical management of spinal extranodal lymphoma. Medical records of 30 patients seen from March 2006 to August 2015, with histologically confirmed spinal lymphoma, were retrospectively reviewed. Demographic information, clinical factors, imaging, treatment and clinical outcomes were recorded. 19 patients were treated surgically and 11 nonsurgically (i.e., chemotherapy, radiation or combination). Surgery was performed for emergent neurological deterioration, mechanical stabilization, refractoriness to medical management or to perform an open biopsy for pathological diagnosis. Among those treated surgically, significantly fewer patients could carry on normal activities (KPS <70) at baseline, compared with those treated nonsurgically. However, there were no significant differences regarding pain medication use, functional status at 1 year, or mean survival (87.6 months) between groups. Surgery for extranodal lymphoma may be required in specific cases, resulting in favorable and similar outcomes compared with nonsurgical management.Entities:
Keywords: Hodgkin lymphoma; adjuvant therapy; lymphoma; spinal instability neoplastic score; spine metastasis; surgery; survival; tumor
Mesh:
Year: 2018 PMID: 29706086 PMCID: PMC5977280 DOI: 10.2217/cns-2017-0033
Source DB: PubMed Journal: CNS Oncol ISSN: 2045-0907
Patient demographics and outcomes.
| Gender, male, n (%) | 19 (63) |
| Median age at diagnosis, years (range) | 63 (5–85) |
| Previous lymphoma diagnosis, n (%)† | 3 (10) |
| Hodgkin | 2 (7) |
| Low grade NHL | 9 (30) |
| Aggressive NHL | 19 (63) |
| Cervical | 1 (3) |
| Thoracic | 14 (47) |
| Lumbar | 13 (43) |
| Multilevel | 2 (7) |
| Chemotherapy alone | 5 (17) |
| Radiotherapy alone | 1 (3) |
| Radiotherapy and chemotherapy | 5 (17) |
| Surgery | 19 (63) |
| Preop – chemotherapy | 2 (13) |
| Preop – radiotherapy | 2 (13) |
| Preop – no exposure | 12 (75) |
| Postop – chemotherapy alone | 9 (56) |
| Postop – radiotherapy alone | 1 (6) |
| Postop chemotherapy and radiotherapy | 6 (38) |
| Patients with known survival | 29 (97) |
| Patients with unknown survival | 1 (3) |
| <3 months survival | 3 (10) |
| 3–12 months survival | 5 (17) |
| >12 months survival | 21 (72) |
| Overall mean survival from Dx, months | 87.6 |
| Surgery group mean survival, months | 79.6 |
| Medical group mean survival, months | 100.4 |
†Median time to spine was 7 years for these three patients. The spine was site of lymphoma presentation for all other patients.
‡Aggressive NHLs include Burkitt and diffuse large cell lymphomas. Low grade NHLs include follicular and small lymphocytic lymphomas.
§Surgery was considered primary treatment for any patient having undergone surgery. Allogenic bone marrow transplant served as salvage therapy for one patient refractory to both radiotherapy and chemotherapy. Two medically treated patients underwent adjuvant cement augmentation for persistent back pain.
¶Three patients had unknown exposure to adjuvant therapy due to being lost to follow-up immediately following surgery and were excluded from analysis of adjuvant therapy. All other surgical patients received an adjuvant therapy pre and/or postoperatively.
Dx: Diagnosis; NHL: Non-Hodgkin lymphoma; Pre-op: Pre-operative.
Functional outcomes.
| Motor deficit/extremity weakness | 1 (9) | 10 (53) |
| Sensory deficit/radiculopathy | 5 (46) | 13 (68) |
| Gait dysfunction | 3 (27) | 11 (58) |
| Sphincter dysfunction | 1 (9) | 4 (21) |
| Duration ≤2 months | 4 (36) | 12 (63) |
| Median | 7 | 6 |
| Mean | 7.2 | 6.2 |
| Stable | 6 (55) | 12 (63) |
| Indeterminate | 4 (36) | 6 (32) |
| Unstable | 1 (9) | 1 (5) |
| Able to carry on normal activity | 11 (100) | 10 (53) |
| Unable to work | 0 (0) | 5 (26) |
| Unable to care for self | 0 (0) | 4 (21) |
| Ambulatory | 11 (100) | 15 (79) |
| Nonambulatory | 0 (0) | 4 (21) |
| Able to carry on normal activity | 7 (100) | 7 (47) |
| Unable to work | 0 (0) | 6 (40) |
| Unable to care for self | 0 (0) | 2 (13) |
| Unknown | 4 (36) | 4 (21) |
| Ambulatory | 7 (100) | 11 (73) |
| Nonambulatory | 0 (0) | 4 (27) |
| Unknown | 0 (0) | 4 (21) |
| Able to carry on normal activity | 7 (100) | 4 (57) |
| Unable to work | 0 (0) | 3 (43) |
| Deceased | 2 (18) | 6 (32) |
| Unknown | 2 (18) | 6 (32) |
| Ambulatory | 7 (100) | 6 (86) |
| Nonambulatory | 0 (0) | 1 (14) |
| Deceased | 2 (18) | 6 (32) |
| Unknown | 2 (18) | 6 (32) |
†Includes patients undergoing radiation therapy.
‡No significant difference between groups by Fisher's exact test.
§Able to carry on normal activity = KPS >70; unable to work but care for most personal needs = KPS 50–70; unable to care for self = KPS ≤40. p = 0.038 by Fisher's exact test.
¶Ambulatory: Frankel D or E; Nonambulatory: Frankel C, B, or A.
♯Percentages exclude deceased and patients with unknown status.
††All patients with known performance status had a KPS >40 at 1 year.
KPS: Karnofsky performance status; SINS: Spinal instability neoplastic score.
Pain medication use.
| 4 | 0 (0) | 2 (11) |
| 3 | 5 (46) | 10 (56) |
| 2 | 3 (27) | 4 (22) |
| 1 | 3 (27) | 2 (11) |
| Unknown | 0 (0) | 1 (5) |
| 4 | 0 (0) | 4 (29) |
| 3 | 3 (43) | 7 (50) |
| 2 | 1 (14) | 3 (21) |
| 1 | 3 (43) | 0 (0) |
| Unknown | 4 (36) | 5 (26) |
| 4 | 1 (14) | 2 (29) |
| 3 | 2 (29) | 2 (29) |
| 2 | 2 (29) | 1 (14) |
| 1 | 2 (29) | 2 (29) |
| Unknown | 2 (18) | 6 (32) |
†Percentages exclude patients with unknown use.
Pain medication scores: 1: No medication; 2: NSAIDs, antiepileptics; 3: Codeine, hydromorphone, oxycodone; 4: Morphine SR/IR, fentanyl via transdermal patch, oxycodone SR/IR; 5: Intravenous narcotics.
Postoperative complications.
| Pulmonary embolus | 2 | 0 |
| Deep vein thrombosis | 1 | 0 |
| Wound dehiscence | 2 | 1 |
| Wound infection | 1 | 1 |
| Ileus | 1 | 0 |
| Epidural hematoma | 1 | 0 |
| Reoperation | 1 | 2 |
†Six total patients experienced complications related to surgery. Values represent number of events.
‡Occurring within 6 weeks of surgery.
Re-admissions.
| Neutropenic fever/sepsis | 11 |
| Other infection | 6 |
| High-dose chemotherapy | 3 |
| Uncontrollable pain | 3 |
| Coagulopathy | 1 |
| Neurological dysfunction | 2 |
| Revision surgery | 1 |
| Dyspnea | 1 |
| Hypotension | 1 |
| Fall | 1 |
| Other† | 1 |
†Removal of Ommaya reservoir & G-tube.
Preoperative representative imaging of a 56-year-old male with large B-cell lymphoma of the spine.
(A) Sagittal CT without contrast. (B) Sagittal T1 MRI. (C) Axial T2 MRI.
CT: Computed tomography.
Postoperative representative imaging of a 56-year-old male with large B-cell lymphoma of the spine.
(A) Sagittal CT without contrast. (B) Sagittal T1 MRI. (C) Axial T2 MRI.
CT: Computed tomography.